Doh Lucius S, Amato Robert, Paulino Arnold C, Teh Bin S
Oncology (Williston Park). 2006 May;20(6):603-13; discussion 613, 616, 619-20 passsim.
Brain metastases from renal cell carcinoma (RCC) cause significant morbidity and mortality. More effective treatment approaches are needed. Traditionally, whole-brain radiotherapy has been used for palliation. With advances in radiation oncology, stereotactic radiosurgery and hypofractionated stereotactic radiotherapy have been utilized for RCC brain metastases, producing excellent outcomes. This review details the role of radiotherapy in various subgroups of patients with RCC brain metastases as well as the associated toxicities and outcomes. Newer radiosensitizers (eg, motexafin gadolinium [Xcytrin]) and chemotherapeutic agents (eg, temozolomide [Temodar]) used in combination with radiotherapy will also be discussed.
肾细胞癌（RCC）脑转移会导致严重的发病率和死亡率。需要更有效的治疗方法。传统上，全脑放疗一直用于姑息治疗。随着放射肿瘤学的进展，立体定向放射外科和低分次立体定向放疗已被用于RCC脑转移，取得了优异的效果。本综述详细介绍了放疗在RCC脑转移患者各个亚组中的作用以及相关毒性和结果。还将讨论与放疗联合使用的新型放射增敏剂（如莫特沙芬钆[Xcytrin]）和化疗药物（如替莫唑胺[Temodar]）。
